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Open access under the ElsA collection of isoxazoles derivatives has been efﬁciently synthesized in three steps. The oximation reac-
tion of aldehydes followed by nitrile oxide [3+2] 1,3-dipolar cycloaddition and MnO2-oxidation reaction
furnished the title compounds which were puriﬁed by simple ﬁltration on celite.
 2011 Elsevier Ltd. Open access under the Elsevier OA license.1. Introduction
Isoxazolines and isoxazoles are important 5-membered hetero-
cycles widely spread out in many compounds with biological and
technological properties. These related ‘cousin’ heterocycles are
also present in a series of important compounds with well known
medicinal properties. For instance, Lee-878, a nitrofuranyl isoxazo-
line is a potent inhibitor against Mycobacterium tuberculosis.1 The
outstanding in vitro activity of this compound led the Lee group
to explore the isoxazolinic core as a privileged structure with
anti-tuberculosis activity.2,3
NO
N
Lee-878
O NO2
NBn: +55 51 33087304.
evier OA license.Nucleosides and nucleotides chemistry are another example of
the exploration of isoxazolines/isoxazole core as substitutes for the
furanose ring in nucleoside analogues.4 These structural modiﬁca-
tions originated a new class of uracils tethered to isoxazolines5 and
isoxazoles6, which showed potential antiviral and anticancer
activity.
Isoxazolines and isoxazoles are substructures also present in
many anti-inﬂammatory drugs, antibacterials,7 in orally bioavail-
able factor Xa inhibitors,8 and display in vitro antiprotozoal activ-
ities.9 These small molecules act as activators of the cystic ﬁbrosis
transmembrane conductance regulator protein (CFTR), in the treat-
ment of lethal genetic disease cystic ﬁbrosis (CF). This disease is
caused by mutations of the CFTR protein.10 Beyond their broad
spectra of biological activity, isoxazolines and isoxazoles are inter-
esting intermediates in organic synthesis,11 and play an important
role in the synthesis of novel liquid-crystalline (LC) materials.12
From the synthetic point of view there are different approaches
to prepare disubstituted isoxazoles. Condensation of 1,3-dicarbonyl
compounds with hydroxylamine,13 Michael addition of hydroxyl-
amine hydrochloride to a,b-insaturated carbonyl compounds
(chalcones) followedby cyclization,14 nucleophilic addition ofN-hy-
droxyl-4-toluenesulfonamide to a,b-unsatd. Aldehydes/ketones15
are representative methods. Besides improvements, many
procedures, have some inherent limitations such as low yields,
Table 1
Thermal data (C) and yield (%) of the isoxazolines 3a–d, 4–13
Entry X Y Yield (%) Mp (C)
3a Br OC7H15 53 119.8
3b Br OC8H17 75 115.8
3c Br OC9H19 54 113.3
3d Br OC10H21 52 111.8
4 Cl OC8H17 43 109.5
5 Me OC8H17 30 94.8
6 Br Br 34 123.2
7 Cl Br 14 120.0
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quently isolated. Other strategies of preparation of regioisomeric
isoxazoles inmoderate yields are possible and involves the thermol-
ysis of haloazidoalkenes and 2-halo-2H-azirines,16 reaction of al-
kynes with ammonium cerium(IV) nitrate [(NH4)2Ce(NO3)6,
CAN(IV)] in acetone,17 diazotization of b-ketoesters followed by
the addition of triethylamine and clorooxime.18 More recently, Lar-
ock’s group reported a three-step approach to synthesize isoxazoles
involving an electrophilic cyclization of the ynone O-methyl
oxime.19
The use of [3+2] 1,3-dipolar cycloaddition of nitrile oxides to al-
kynes constitutes an important alternative to prepare isoxazoles in
solution or by combinatorial synthesis on solid support.20 In fact,
many nitrile oxides react with alkynes, with few exceptions,21
leading often to a mixture of regioisomeric products, with low
yields. To overcome this trouble Sharpless and co-workers re-
ported that nitrile oxides react with alkynes at appreciable rates
at room temperature in a highly selective manner and with good
yields when copper(I) catalyst was added.22 The performance of
this procedure was also applied later in the synthesis of liquid crys-
tals by Gallardo et al.23 Although some alkynes are commercially
available, the synthesis of mono-substituted alkynes can take
two or more steps. In this sense, alkyne synthons can serve to alle-
viate the issues related on both alkyne preparation and cycloaddi-
tion regioselectivity.24
In our search for new LC molecules we have demonstrated the
versatility of the [3+2] 1,3-dipolar cycloaddition as a suitable
methodology to access a variety of 3,5-disubstituted isoxazoline
liquid crystals.25 Our previous results showed that the introduction
of an isoxazoline ring ﬂanked by aromatic rings or polar groups
opened a route to prepare useful intermediates in the liquid crys-
tals ﬁeld, from themselves or their parent compounds isoxazoles.
During the course of our investigation about isoxazolines, as a
molecular kit for LC, we selected one of them and subjected it to
a MnO2-mediated oxidation process. We found that this reagent
can easily oxidize 3,5-diarylisoxazoline to the corresponding
3,5-diarylisoxazole yielding LC materials with a large enantiotropic
nematic mesophase.26
Herein we wish to report a facile and efﬁcient synthesis of a
collection of 3,5-disubstituted isoxazoles liquid crystals from isox-
azolines, using the couple nitrile oxide [3+2] 1,3-dipolar cycloaddi-
tion/MnO2-oxidation reactions.
In addition, halogenated variants of these core motifs open to us
an avenue to be explored as starting materials for palladium-cata-
lyzed reactions. So, the preparation of small molecular organic
intermediate with potential technological applications, such as or-
ganic light-emitting diodes (OLEDs), organic ﬁeld-effect transistors
(OFETs) and liquid crystal displays (LCDs) can be achieved once it is
an important task in the ﬁeld of organic electronic materials-
OEM.27
2. Results and discussion
Scheme 1 outlines the preparation of a general collection of
isoxazolines and isoxazoles in a short and efﬁcient sequence. Thus,
aliphatic and aromatic aldehydes 1were ﬁrst converted into aldox-
imes by treatment with a hydroxylamine hydrochloride solution.N O
R'R
R
O
H
1.NH2OH.HCl, 
   H2O/EtOH,
2. NCS, py, DCM,
p-XC6H4CH=CH2 (2)
N O
R'R3. MnO2,
1 Isoxazolines
Na2CO3, C6H6
Isoxazoles
X = Br, Cl, Me, t-ButO
Scheme 1. Synthesis of isoxazoles from isoxazolines by [3+2] 1,3-dipolar cycload-
dition followed by MnO2-oxidation reaction.The mixture was heated under reﬂux for 40 min, concentrated
and left in the freezer overnight to give pure products as white sol-
ids. Next, using the [3+2] 1,3-dipolar cycloaddition reaction were
prepared the key isoxazolines 3–13, 25a–b, and 26a–b containing
suitable groups for chemical transformations. These compounds
were synthesized starting with the 1,3-dipolar component nitrile
oxide, which was obtained in situ by reacting the aldoxime deriv-
atives with NCS in pyridine28, followed by the addition of a solu-
tion of different acceptors 2, at room temperature for 4 h. The
low yields observed in some examples are related with the low sol-
ubility of some oximes. The preparation of these isoxazolines
derivatives provided us with an entry of a new class of precursors
for high-performance liquid crystals materials.
With the valuable target intermediates 3,5-diarylisoxazolines
synthesized, we focused our attention toward the transformation
of them to isoxazoles through the oxidation protocol using acti-
vated cMnO2 reagent.29 The results are presented in Tables 1
and 2.
In order to determine the best reaction condition on the
oxidation step, several other reagents were also tested30 and the
best results were obtained using activated MnO2 oxidant in a
Dean–Stark apparatus. By simple ﬁltration and remotion of the
solvent the ﬁnal isoxazoles were synthesized in good to excellent
yields.
All halogenated compounds synthesized are versatile building
blocks that may be incorporated into low molar mass mesogenic
structures for potential use on optical applications. The bromine
atom at para position of the benzene ring offers the possibility to
carry out a palladium-catalyzed cross-coupling reaction, which
would lead to a very broad range of compounds with interesting
properties in the ﬁeld of organic materials.31
For example, compounds 23b and 24b could be valuable inter-
mediates in the synthesis of bent core liquid crystals.32 They are
synthesized according to Scheme 2 where the delivery of free phe-
nol 23b is accomplished by the remotion of t-butyl group in AcOH/
HBr medium. The alkylation of 23b yields LC 23c.
In order to extend the scope of our methodology, aliphatic
aldoximes were also used as precursors for the nitrile oxides. The
data collected in Table 3 show that the preparation of 3-alkyl-5-
arylisoxazoline 25a–b and 26a–b and the corresponding isoxazoles
27a–b and 28a–b is an attractive alternative to obtain advanced
synthetic intermediates in the ﬁeld of functional materials.
In fact, as can be seen from the results presented until now, the
preparation of isoxazoles from isoxazolines constitutes of an
alternative very efﬁcient, fast, and clean method to reach useful
intermediates in areas such as OEM and functional materials. Some8 Me Br 93 142.5
9 Br NO2 42 132.0
10 Cl NO2 19 140.5
11 Me NO2 14 122.0
12 tButO Br 57 122.0
13 tButO NO2 20 143.0
NO
YX
Table 2
Transition temperaturesa (C) and yield (%) of the isoxazoles 14a–d, 15–24b
Entry X Y Yield (%) Physical appearance
14a Br OC7H15 99 Cr 109.3 CrE 128.0 SmA 191.3 I
14b Br OC8H17 98 Cr 93.0 CrE 129.0 SmA 191.0 I
14c Br OC9H19 50 Cr 108.6 CrE 126.0 SmA 184.5 I
14d Br OC10H21 97 Cr 99.0 CrE 128.0 SmA 186.0 I
15 Cl OC8H17 70 Cr 115.5 CrA 180.0 N 184.0 I
16 Me OC8H17 90 Cr 105.9 N 132.2 I
17 Br Br 94 Cr 214.4 I
18 Cl Br 47 Cr 200.0 I
19 Me Br 67 Cr 210.0 I
20 Br NO2 62 Cr 224.8 I
21 Cl NO2 66 Cr 222.2 I
22 Me NO2 70 Cr 182.5 I
23a t-ButO Br 95 Cr 157.8 I
24a t-ButO NO2 95 Cr 181.0 I
NO
YX
a Data obtained by polarizing optical microscopy, POM; Cr = crystal phase;
CrE = Crystal E phase; SmA = Smectic A phase and I = Isotropic phase.
NO
YRO
23a R = t-But, Y = Br
23b R = H, Y = Br a. AcOH, HBr, MeOH(99%, mp 205.5 oC for 23b
98%, mp 241.0 oC for 24b)
a
24a R = t-But, Y = NO2
24b R = H, Y = NO2
a
23c R = OC 8H17, Y = Br
b
b. RBr, CH3CN, K2CO3, (84%)(Cr 98.8 CrE 119.5 SmA 191.0 I)
Scheme 2. Preparation of phenols 23b and 24b by deprotection reaction of 23a and
24a and the corresponding alkylated 23c.
Table 3
Thermal data (C) and yield (%) of the isoxazolines 25a,b–26a,b and isoxazoles 27a,b–
28a,b, respectively
Entry R X Yield (%) Mp (C)
25a C4H9 Br 25 a
25b C4H9 Me 44 a
26a C7H15 Br 87 a
26b C7H15 Me 49 a
X
NO
R
27a C4H9 Br 48 48.3
27b C4H9 Me 89 a
28a C7H15 Br 70 76.0
28b C7H15 Me 72 55.5
NO
R
X
a Viscous liquid at room temperature.
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Scheme 3. Stepwise reaction sequence for the manganese dioxide oxidation of
isoxazoline 6.
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E phase founded in these compounds makes them very promising
candidates for their application in the ﬁeld of OFETs. It is interest-
ing to see that exchanging the terminal groups in 14a–d to 23c
does not modify the nature of the mesophase. We anticipated that
the optical texture of the liquid crystalline A phase of compound
14a, viewed between crossed polarisers (see SI) on cooling, is
transferred to the smectic E phase, and then to the crystalline state.
This paramorphosis phenomenon is important to control the short-
range spatial order present in the smectic phases on cooling.33Also, the nature of mesophase is dependent on the terminal group
attached in the para position of benzene ring if we compare 14d,
15, and 16.34 As expected all isoxazolines in Tables 1 and 3 are
not liquid crystals considering that they are not completely conju-
gate and planar.
The 3-alkyl-5-arylisoxazoles 27a–b and 28a–b are other precur-
sors for obtaining new low molar mass liquid crystal.35 These new
precursors have the benzene ring substituted by short and medium
alkyl chain at C-3 position of the isoxazole ring. The properties
could be tailored by changing the molecular shape. A detailed
synthetic study of preparation of the new compounds from these
isoxazoles is now in progress and will be reported soon.
The mechanistic proposal for the formation of 3,5-disubstituted
isoxazoles from 3,5-disubstuted isoxazolines with activated man-
ganese dioxide is shown in Scheme 3. The mechanism of oxidation
of benzyl alcohol with manganese dioxide has been studied by
Goldman.36 According to his studies, the rate-determining step in
the oxidation of benzyl alcohols with activated manganese dioxide
involves the cleavage of the a-CH bond, and that the assumed
adsorption step is reversible. More recently, Srivastava et al. re-
ported the conversion of 4,5-dihydro-1,2,4-oxadiazoles to 1,2,4-
oxadiazoles by an oxidation process mediated by MnO2 and NaOCl
reagents.37 The mechanism of this transformation was discussed
by the authors. Similar mechanism should be considered for the
oxidation of 3,5-disubstituted isoxazolines to 3,5-disubstituted
isoxazoles as exempliﬁed by 6 to 17 (Scheme 3). Initially, 6 inter-
acts reversibly at the surface of manganese dioxide via coordina-
tion between N and MnO2 forming the complex I (to activate the
Ha-iminic hydrogen), which undergoes oxidation via hydrogen-
atom transfer from I to another equivalent of MnO2 to form the sta-
ble radical II. Abstraction of a hydrogen radical from C-3 generates
III, which then is dissociated delivering the isoxazole 17 and the
inorganic species (MnO2, MnO, and H2O).
In summary, we have synthesized a collection of isoxazoles
which are rapidly accessed by two efﬁcient methodologies—the
nitrile oxide [3+2] 1,3-dipolar cycloaddition followed by MnO2-
oxidation reaction. The ﬁnal isoxazoles are valuable building
blocks which may be transformed into potential materials in
OEM or functional materials.
3. Experimental section
3.1. Synthesis
4-n-Alkyloxybenzadehyde and the corresponding oximes were
prepared according to Refs. 25,26. The general procedure for the
preparation of 3,5-disubstituted isoxazolines is described as fol-
lows: To a solution of alkene (4.25 mmol) in CH2Cl2 (10 ml), at
0 C and under inert atmosphere, were added NCS (4.67 mmol)
6572 G. D. Vilela et al. / Tetrahedron Letters 52 (2011) 6569–6572and pyridine (6.37 mmol). A solution of aldehyde oxime
(4.25 mmol) in CH2Cl2 (12 ml) was added dropwise and stirred
for 4 h at room temperature. The mixture was washed with HCl
1 M (3  20 ml), brine, (2  20 ml) and dried over anhydrous
Na2SO4. Removal of CH2Cl2 afforded the crude product, which
was recrystallized from ethanol to give the pure product as a white
solid or isolated by column chromatography using a mixture of
EtOAc/hexane (1:9).
General procedure for the oxidation reaction. To a ﬂask adapted
with a Dean-Stark were added 3,5-disubstituted isoxazoline
(1.2 mmol), benzene (25 ml), and c-MnO2 (6 mmol). The mixture
was heated under reﬂux for 10 hours. After that, it was ﬁltered over
celite and concentrated in vacuum to give a pale white solid which
was puriﬁed by recrystallization in ethanol. Data for 14a. Yield:
99%; mp 109.3 C; 1H NMR (300 MHz, CDCl3) d 7.76 (d, 2H,
J = 8.4 Hz, Ar), 7.68 (d, 2H, J = 8.7 Hz, Ar), 7.60 (d, 2H, J = 8.4 Hz,
Ar), 6.97 (d, 2H, J = 8.4 Hz, Ar), 6.76 (s, 1H), 4.00 (t, 2H, J = 6.4 Hz,
OCH2CH2), 1.81 (m, 2H, OCH2CH2), 1.5–1.3 (m, 8H, (CH2)4), 0.90
(t, 3H, J = 6.4 Hz, CH3); 13C NMR (75.5 Hz, CDCl3) d 169.0, 162.7,
160.7, 132.2, 128.1, 127.3, 127.2, 126.4, 124.4, 121.1, 114.8, 97.6,
68.1, 31.8, 29.2, 29.0, 26.0, 22.6; Elem. Anal. Calcd for C22H24NO2Br:
C, 63.77; H, 5.84; N, 3.38. Found: C, 63.63; H, 5.63; N, 3.42.
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